Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
25 mai 2021 08h00 HE
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Central Nervous System Treatment Market to Reach USD 166.53 Billion with a CAGR of 9.4% by 2028; Rising Cases of Neurological Disorders to Propel Growth: states Fortune Business Insights™
22 mars 2021 05h51 HE
|
Fortune Business Insights
Pune, India, March 22, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to reach USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
17 mars 2021 07h00 HE
|
Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...
Nerve Control 911 Reviews: Negative Side Effects or Legit Ingredients? 2021 Review
12 mars 2021 13h56 HE
|
2021Review.com
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- Nerve Control 911 is a daily remedy for the central nervous system, supporting the communication to the organs and muscles. The formula is easy to take...
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
28 janv. 2021 08h05 HE
|
Aeterna Zentaris Inc
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...
Report 2021, Central Nervous System Treatment Market Size, Share, Growth, Trends, Analysis, Revenue, Forecast Report – 2020-2027
25 janv. 2021 06h25 HE
|
Fortune Business Insights
Pune, India, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to gain momentum in the forthcoming years. This is attributable to the increasing...
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
28 déc. 2020 08h00 HE
|
CNS Pharmaceuticals, Inc.
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
24 nov. 2020 08h00 HE
|
CNS Pharmaceuticals, Inc.
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
Rare Disease Treatment Market revenue to cross USD 317 Bn by 2026: Global Market Insights, Inc.
19 nov. 2020 04h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 19, 2020 (GLOBE NEWSWIRE) -- According to latest report “Rare Disease Treatment Market by Drug Type (Biologics, Non-biologics), Therapeutic Area (Cancer, Blood-related...
Global Surgical Sealants and Adhesives Market Is Expected to Reach USD 4.34 billion by 2027 : Fior Markets
17 sept. 2020 04h00 HE
|
Fior Markets
Newark, NJ, Sept. 17, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global surgical sealants and adhesives market is expected to grow from USD 2.08 billion in 2019 and to...